TABLE I.

Cohort Demographics, Pathologic Characteristics, and Outcomes

	CA 19-9 ≤ 37, n = 938	CA 19-9 > 37, n = 1,878	P
Median age (IQR)	65.00 (56.00, 74.00)	66.00 (57.00, 75.00)	0.008
Female sex	53.1%	47.4%	0.005
Race			0.165
Caucasian	82.9%	84.3%
African American	9.6%	7.6%
Other	7.5%	8.1%
Charlson–Deyo score			0.641
0	64.3%	65.5%
1	23.6%	22.0%
2+	12.2%	12.5%
Facility type			0.015
Community	4.9%	7.2%
Comprehensive community	29.9%	33.0%
Academic/research	60.6%	55.0%
Integrated network	4.6%	4.7%
Year of diagnosis			<0.628
2010	25.8%	26.8%
2011	35.7%	33.9%
2012	38.5%	39.2%
Stage (%)			<0.001
Stage I	18.2%	10.3%
Stage II	14.4%	12.2%
Stage III	7.3%	6.0%
Stage IV	41.7%	53.7%
Stage unavailable	18.4%	17.7%
Median tumor sizea	5.0	5.4	0.110
N1 statusa	28.7%	43.8%	<0.001
High gradea	32.0%	35.7%	0.516
Lymphovascular invasiona	38.3%	46.5%	0.200
Positive margina	14.7%	20.4%	0.165
Radiation	17.7%	14.6%	0.090
Chemotherapy	56.6%	53.2%	0.225
Chemo surgery sequence			<0.001
No surgery	67.0%	83.0%
Surgery alone	20.2%	7.9%
Neoadjuvant	4.3%	3.0%
Surgery then adjuvant	8.5%	6.1%
30-day readmissiona	6.2%	9.1%	0.058
Median hospital stay (days)a	9.5	11.2	0.143
30-day mortalitya	4.2%	4.5%	0.110
90-day mortalitya	6.2%	13.2%	0.004
Median OS (months)
All patients	14.6	6.6	0.003
Resected patients	47.8	22.6	<0.001
Interval survival (all patients)
1-year	54.9%	34.6%	<0.001
2-year	37.3%	17.0%	<0.001
3-year	26.5%	11.1%	<0.001
Interval survival (resected)a
1-year	84.7%	71.2%	<0.001
2-year	70.5%	48.6%	<0.001
3-year	50.7%	40.8%	<0.001

^aAmong resected patients, with evaluable data.